Cassaday & Co Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Cassaday & Co Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.7K	Buy	+840	New	+$20.1K	﹤0.01%	797

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cassaday & Co Wealth Management's ACAD Position: Q1 2026 in Review

Cassaday & Co Wealth Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 840 shares worth $18.7K. The stake represents ﹤0.01% of the portfolio and ranks #797 among its holdings.

340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Cassaday & Co Wealth Management held 840 shares of Acadia Pharmaceuticals worth $18.7K as of Q1 2026.
Acadia Pharmaceuticals was a new Cassaday & Co Wealth Management position in Q1 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q1 2026, its #797 holding.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.